Fennec Pharmaceuticals Inc. (FENC) Research

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Market snapshot

Symbol
FENC
Price
$9.06
Day change
+0.89%
Market cap
$258.9M
P/E ratio
-37.14x
52-week range
5.65-10.45
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$17.00

Recent news

  • Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

    Fennec Pharmaceuticals Inc. (NASDAQ: FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.

Peer companies

  • Aardvark Therapeutics, Inc. Common Stock (AARD)
  • Avalo Therapeutics, Inc. (AVTX)
  • Black Diamond Therapeutics, Inc. (BDTX)
  • Caribou Biosciences, Inc. (CRBU)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Eupraxia Pharmaceuticals Inc. (EPRX)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Orchestra BioMed Holdings, Inc. (OBIO)

Recent insider activity

  • Brughera Marco Maria — A-Award (20000 shares) on 2026-06-10
  • Cook Jodi A — A-Award (20000 shares) on 2026-06-10
  • Islam Khalid — A-Award (25000 shares) on 2026-06-10
  • RALLIS CHRIS A — A-Award (20000 shares) on 2026-06-10
  • Raykov Rosty — M-Exempt (15597 shares) on 2026-06-01

Open Fennec Pharmaceuticals Inc. (FENC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.